avasopasem (Pending FDA Approval)

Brand and Other Names:

Dosing & Uses

Mucositis

Pending FDA approval for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer

Next:

Pharmacology

Mechanism of Action

Mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to reduce oral mucositis and esophagitis associated with radiation therapy and chemoradiotherapy

Upon administration, avasopasem manganese may mimic native SODs and catalyze formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in irradiated tissues upon radiation

This may decrease radiation damage to normal tissues

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.